Read the official Press Release here
WHIPPANY, N.J. — ConnectiveRx, a leading provider of technology-enabled patient support and access solution for branded and specialty medications, today announced the launch of ShieldRx, a pharmacy monitoring and misuse prevention engine developed in partnership with EagleForce, a leader in secure health data, real-time verification technologies, and pharmaceutical risk intelligence.
As manufacturers face escalating pressure on gross‑to‑net performance driven by payer tactics, accumulator and maximizer programs, and growing pharmacy misuse, traditional post‑pay audits and retrospective controls are no longer sufficient. ShieldRx delivers proactive, in‑workflow protection that identifies and stops suspect activity before claims are paid.
The latest solution in ConnectiveRx’s robust Gross-to-Net Protection platform, ShieldRx combines ConnectiveRx’s expertise in affordability program design and real‑time adjudication with EagleForce’s advanced identity, compliance, and transaction‑level intelligence to deliver the industry’s first fully integrated pharmacy misuse prevention solution embedded directly into the pharmacy workflow.
Pharmacy misuse and invalid copay behavior contribute to $5B in manufacturer revenue loss each year. ShieldRx was developed to confront this problem head‑on through:
- AI‑driven risk models trained on large‑scale pharmacy, patient, prescriber, and historical claims data to surface statistically abnormal behavior
- Real‑time, in‑workflow risk scoring that identifies suspect transactions before payment
- High‑speed claim evaluation returning pass/fail decisions in seconds
- A pharmacist‑accessible resolution center enabling immediate follow‑up, verification, and documentation
By intercepting and preventing invalid activity in real time, ShieldRx enables manufacturers to safeguard copay investments, strengthen program integrity, and ensure affordability funds are used as intended while deploying seamlessly within existing pharmacy workflows.
“Manufacturers are under unprecedented pressure to protect gross‑to‑net performance without disrupting patient access,” said Cindy Baksh, Chief Product Officer, ConnectiveRx. “ShieldRx sets a new standard for proactive oversight, giving brands real‑time protection, clearer insight, and greater confidence in the integrity of every claim.”
“ShieldRx represents a game-changing advancement in how manufacturers protect gross‑to‑net,” said Stanley Campbell, Jr. Chief Executive Officer, EagleForce. “By combining EagleForce’s real‑time identity and transaction intelligence with ConnectiveRx’s embedded pharmacy workflows and scale, manufacturers can identify and stop suspect behavior in seconds, before payment, without disrupting legitimate patient access.”
Pilot implementations across high-volume brands have already demonstrated impressive detection performance, operational readiness, and strong ROI.